Asset Details
Do you wish to reserve the book?
Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation
Do you wish to request the book?
Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation
2025
Overview
Background
Triple-negative breast cancer (TNBC) has the poorest prognosis among the three major subtypes of breast cancer, and more than one-third of patients with TNBC experience recurrence or distant metastasis. Despite advances in diverse immunotherapy strategies for metastatic TNBC (mTNBC), multiple mechanisms underlying resistance to treatment remain unknown.
Methods
In this study, the dynamic changes in the immune landscape in mTNBC were assessed and compared with healthy donors using single-cell RNA sequencing (scRNA-seq) analysis. By integrating internal and public scRNA-seq data, 61,149 cells extracted from East Asian patients with mTNBC and 51,448 cells extracted from East Asian healthy donors were used to landscape a comprehensive cellular profile of mTNBC.
Results
Results showed that nine overexpressed genes from patients with mTNBC in effector T cells such as
CTSW
,
PRF1
,
GNLY
,
GZMA
,
CCL5
,
KLRD1
,
KLRB1
,
B2M
, and
GZMB
exhibited favorable survival prognoses. In addition, effector T cells enriched in patients with mTNBC were more differentiated compared with those enriched in healthy donors.
Conclusion
Collectively, this study is the first to provide potential diagnostic and therapeutic targets of East Asian chemotherapy-treated mTNBC with regard to effector T cells.
